Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men
- 9 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 17 (8) , 1544-1552
Abstract
Background: Compulsive sexual behavior disorder (CSBD) is a common disorder affecting different areas of life, although studies focusing on pharmacological treatment are sparse. Aim: To investigate whether the opioid receptor antagonist naltrexone is feasible and tolerable and can provide symptom reduction in CSBD. Methods: Twenty men aged 27–60 years (mean = 38.8 years, standard deviation = 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of naltrexone 25–50 mg. Measurements were made before, during, and four weeks after treatment. Outcomes: The self-assessment Hypersexual Disorder: Current Assessment Scale (HD: CAS) score was the primary outcome measure, and secondary outcomes were the Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts. Results: There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone. Even though some of the effects remained after treatment, the increased scores on HD: CAS indicated worsening of CSBD symptoms. The most reported side effects were fatigue (55%), nausea (30%), vertigo (30%), and abdominal pain (30%). However, there were no serious adverse effects leading to discontinuation of naltrexone. Clinical Implications: Despite side effects being common, naltrexone seems to be feasible in the treatment of CSBD. Strengths & Limitations: Being the first nonforensic prospective trial on naltrexone in CSBD, this study provides novel insights on a pharmacological intervention. However, owing to the small sample size and the lack of a control group, conclusions of effectiveness should be interpreted with caution. Conclusion: Naltrexone is feasible and tolerable and may reduce symptoms of CSBD; nevertheless, future studies should ensure a randomized controlled procedure to evaluate possible effectiveness.Keywords
Funding Information
- Umeå University and Västerbotten County Council (RV 747701, RV 864171)
- Anova Health Institute
- Västerbotten Läns Landsting
- Stockholms Läns Landsting (RV 747701, RV 864171)
- Umeå Universitet
This publication has 36 references indexed in Scilit:
- Reliability, Validity, and Psychometric Development of the Hypersexual Behavior Inventory in an Outpatient Sample of MenSexual Addiction & Compulsivity, 2011
- The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphiliasThe World Journal of Biological Psychiatry, 2010
- Hypersexual Disorder: A Proposed Diagnosis for DSM-VArchives of Sexual Behavior, 2009
- Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2008
- Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent PeopleArchives of General Psychiatry, 2008
- Internet Sex Addiction Treated With NaltrexoneMayo Clinic Proceedings, 2008
- Evaluation of the Drug Use Disorders Identification Test (DUDIT) in Criminal Justice and Detoxification Settings and in a Swedish Population SampleEuropean Addiction Research, 2004
- Psychiatric comorbidity and compulsive/impulsive traits in compulsive sexual behaviorComprehensive Psychiatry, 2003
- The paraphilia-related disorders: An empirical investigation of nonparaphilic hypersexuality disorders in outpatient malesJournal of Sex & Marital Therapy, 1999
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983